SteadyMed Ltd. (NASDAQ:STDY) released its quarterly earnings results on Friday. The company reported ($0.33) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by $0.01, MarketWatch Earnings reports. The company had revenue of $0.32 million for the quarter, compared to analyst estimates of $0.26 million. SteadyMed had a negative net margin of 3,759.61% and a negative return on equity of 240.57%.

Shares of SteadyMed (NASDAQ:STDY) traded down 1.98% during trading on Friday, hitting $6.20. The stock had a trading volume of 9,027 shares. The firm’s market cap is $156.06 million. SteadyMed has a 52-week low of $2.25 and a 52-week high of $9.70. The stock has a 50 day moving average of $6.35 and a 200 day moving average of $5.58.

COPYRIGHT VIOLATION NOTICE: This article was first posted by Daily Political and is the sole property of of Daily Political. If you are reading this article on another publication, it was copied illegally and reposted in violation of US & international trademark & copyright legislation. The original version of this article can be viewed at https://www.dailypolitical.com/2017/08/12/steadymed-ltd-stdy-issues-earnings-results.html.

Separately, Zacks Investment Research upgraded SteadyMed from a “sell” rating to a “hold” rating in a research note on Tuesday, July 18th.

About SteadyMed

SteadyMed Ltd. is a specialty pharmaceutical company. The Company is focused on the development and commercialization of various therapeutic product candidates. Its primary focus is to obtain approval in the United States for the sale of Trevyent for the treatment of pulmonary arterial hypertension (PAH).

Earnings History for SteadyMed (NASDAQ:STDY)

Receive News & Ratings for SteadyMed Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SteadyMed Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.